The Green House Project, Linthicum, MD

The Green House Project

www.thegreenhouseproject.org

More than 18 years since the first Green House homes opened, THE GREEN HOUSE® Project (GHP) has come to be recognized as the leader in creating high-quality, cost-effective, and sustainable, human-scale alternatives to the traditional nursing home. The pace of momentum continues to increase, now with the majority of states having Green House homes, and potential of global expansion. By infusing the entire organization with optimal systems and structural changes that create a unified approach to elder-directed care, GHP creates a disruptive and high impact innovation. GHP means much more than simply building a small house, it is a movement ...

More>>

Number of Employees: 25-100
Annual Revenue: $1-10 Million

www.thegreenhouseproject.org
849 International Drive
Linthicum, MD USA 21090
Phone: 410.246.3806

Similar Companies

Discovery Laboratories Inc

Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.

CLOs on the Move